Although the 14-gene model from the PurIST study and GATA6 as a single-gene model have been selected as benchmark classifiers for pancreatic cancer, we recommend ITGA3 as a promising supplementary marker for determining the immunotherapy or chemotherapy refractory status of patients with pancreatic cancer, regardless of the sampling location. The gene discussed is GATA6; the disease is pancreatic neoplasm.